Gylden Pharma

Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, Oxfordshire, UK, with R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, UK, an operating subsidiary in Doylestown, Pennsylvania, USA and a manufacturing facility in Fremont, CA, USA. The Company is pioneering the development of synthetic T cell-priming vaccines/immunotherapies designed to mimic the body’s natural cellular immune response to destroy and clear pathogen-infected cells to protect against some of the world’s most urgent health threats. The candidates are designed for delivery via novel skin immunisation into the epidermal layer, aiming to ease the burden and logistics of traditional preventative methods. Gylden’s first indications pursued are against infectious diseases:[i] including core candidates for Betacoronaviruses, Dengue Fever and Universal Influenza (including Pandemic Influenza), as well as [ii] intra-cellular bacterial infectious disease. Additional products include a patch-based therapeutic drug for migraine, and candidates for cardiometabolic disorders, as well as cancer immunotherapy. Gylden's product pipeline includes innovative candidates with potential for rapid, broad, and long-lasting prevention of viral infections as well as immunotherapies in other therapeutic categories. Gylden’s T cell-priming vaccines and immunotherapy candidates combine core technologies,[i] a proprietary MHC Class I “Ligandome Library" of experimentally-selected peptide antigens expressed on the surface of pathogen-infected cells, using Immunoproteomics and Multi-Omic technologies,[ii] a proprietary ultrasmall carbohydrate-passivated nanocluster carrier system designed to deliver synthetic peptides to the skin-resident immune system to elicit robust T cell Microneedle Array Patch (MAP) transdermal delivery technology acquired from Zosano Pharma in 2022, and [iv] in-house GMP accredited nanomedicine manufacturing capabilities.